{"id":77742,"date":"2026-09-01T12:11:46","date_gmt":"2026-09-01T04:11:46","guid":{"rendered":"https:\/\/flcube.com\/?p=77742"},"modified":"2026-09-01T12:11:47","modified_gmt":"2026-09-01T04:11:47","slug":"cspc-pharmaceutical-initiates-phase-i-trial-of-amylin-receptor-agonist-syh2092-for-weight-management-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77742","title":{"rendered":"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>)<\/strong> announced that the <strong>Phase I clinical trial<\/strong> of <strong>SYH2092<\/strong>, an <strong>amylin receptor agonist<\/strong> for <strong>weight management<\/strong> in adult patients with <strong>overweight or obesity<\/strong>, has been officially initiated at its first study site in <strong>China<\/strong>. The milestone marks <strong>CSPC<\/strong>&#8216;s formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.<\/p>\n\n\n\n<h2 id=\"h-development-milestone\" class=\"wp-block-heading\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Sponsor<\/td><td><strong>CSPC Pharmaceutical Group (HKG: 1093)<\/strong><\/td><\/tr><tr><td>Candidate<\/td><td><strong>SYH2092<\/strong> (amylin receptor agonist)<\/td><\/tr><tr><td>Indication<\/td><td>Weight management in adults with <strong>overweight or obesity<\/strong><\/td><\/tr><tr><td>Event<\/td><td>Phase I clinical trial officially initiated at first study site<\/td><\/tr><tr><td>Location<\/td><td><strong>China<\/strong><\/td><\/tr><tr><td>Announcement Date<\/td><td><strong>31 Aug 2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>SYH2092<\/strong>, an <strong>amylin receptor agonist<\/strong> developed by <strong>CSPC Pharmaceutical Group<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Activates amylin signaling pathways involved in satiety and appetite regulation \u2014 a complementary route to GLP\u20111-based therapies in obesity<\/li>\n\n\n\n<li><strong>Preclinical Differentiation:<\/strong> Versus several <strong>amylin analogs<\/strong> currently in clinical development, <strong>SYH2092<\/strong> demonstrated:\n<ul class=\"wp-block-list\">\n<li>Higher target agonistic activity<\/li>\n\n\n\n<li>Significant weight-loss efficacy in preclinical models<\/li>\n\n\n\n<li>Sustained weight-maintenance effect<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Extends <strong>CSPC<\/strong>&#8216;s metabolic pipeline into the high-demand obesity and weight-management landscape<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Entry Into a Crowded Race:<\/strong> The initiation of Phase I places <strong>CSPC<\/strong> among companies pursuing next-generation anti-obesity mechanisms beyond GLP\u20111, with amylin agonism seen as a promising complementary pathway<\/li>\n\n\n\n<li><strong>Preclinical Edge Claimed:<\/strong> The stated advantages over clinical-stage <strong>amylin analogs<\/strong> \u2014 stronger agonistic activity, weight-loss efficacy, and durable maintenance \u2014 will need clinical validation but provide an early differentiation narrative<\/li>\n\n\n\n<li><strong>Weight-Maintenance Angle:<\/strong> Sustained weight maintenance addresses a known limitation of current obesity therapies, where weight regain after discontinuation remains a key clinical challenge<\/li>\n\n\n\n<li><strong>China Market Opportunity:<\/strong> <strong>China<\/strong> represents one of the world&#8217;s largest populations of adults with overweight or obesity, offering substantial commercial headroom for differentiated <strong>weight management<\/strong> therapies<\/li>\n\n\n\n<li><strong>Catalyst Watch:<\/strong> Phase I safety and pharmacokinetic readouts will be the near-term catalysts for <strong>CSPC Pharmaceutical Group (HKG: 1093)<\/strong> as the program advances<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward-looking statements regarding clinical development, preclinical findings, and market potential that involve risks and uncertainties. Preclinical results are not indicative of clinical outcomes. Nothing herein constitutes investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026083101886_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026083101886_c.\"><\/object><a id=\"wp-block-file--media-913a6f38-cdf1-4484-862e-935dc35bd41d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026083101886_c.pdf\">2026083101886_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026083101886_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-913a6f38-cdf1-4484-862e-935dc35bd41d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,171,855,86],"class_list":["post-77742","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an amylin receptor agonist for weight management in adult patients with overweight or obesity, has been officially initiated at its first study site in China. The milestone marks CSPC&#039;s formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77742\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an amylin receptor agonist for weight management in adult patients with overweight or obesity, has been officially initiated at its first study site in China. The milestone marks CSPC&#039;s formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77742\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T04:11:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T04:11:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77742#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77742\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China\",\"datePublished\":\"2026-09-01T04:11:46+00:00\",\"dateModified\":\"2026-09-01T04:11:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77742\"},\"wordCount\":367,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77742#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77742\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77742\",\"name\":\"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-01T04:11:46+00:00\",\"dateModified\":\"2026-09-01T04:11:47+00:00\",\"description\":\"CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an amylin receptor agonist for weight management in adult patients with overweight or obesity, has been officially initiated at its first study site in China. The milestone marks CSPC's formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77742#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77742\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77742#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an amylin receptor agonist for weight management in adult patients with overweight or obesity, has been officially initiated at its first study site in China. The milestone marks CSPC's formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77742","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China","og_description":"CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an amylin receptor agonist for weight management in adult patients with overweight or obesity, has been officially initiated at its first study site in China. The milestone marks CSPC's formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.","og_url":"https:\/\/flcube.com\/?p=77742","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-01T04:11:46+00:00","article_modified_time":"2026-09-01T04:11:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77742#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77742"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China","datePublished":"2026-09-01T04:11:46+00:00","dateModified":"2026-09-01T04:11:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77742"},"wordCount":367,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77742#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77742","url":"https:\/\/flcube.com\/?p=77742","name":"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-01T04:11:46+00:00","dateModified":"2026-09-01T04:11:47+00:00","description":"CSPC Pharmaceutical Group (HKG: 1093) announced that the Phase I clinical trial of SYH2092, an amylin receptor agonist for weight management in adult patients with overweight or obesity, has been officially initiated at its first study site in China. The milestone marks CSPC's formal entry into first-in-human testing of a candidate positioned against the fastest-growing frontier in metabolic disease \u2014 the obesity drug race.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77742#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77742"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77742#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Initiates Phase I Trial of Amylin Receptor Agonist SYH2092 for Weight Management in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77742"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77742\/revisions"}],"predecessor-version":[{"id":77745,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77742\/revisions\/77745"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77742"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77742"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}